iRhythm Holdings, Inc. Common Stock

iRhythm's 9.28% short interest represents meaningful bearish conviction, yet the RSI of 44.2 signals oversold conditions rather than a top-heavy setup. With a $4.0B market cap in medical devices and the stock trading below its 52-week high, the valuation appears undemanding relative to the competitive position in cardiac monitoring. The absence of a reported P/E ratio suggests either negative earnings or a cash-burn profile typical of growth-stage medtech, warranting scrutiny of profitability timelines. A combination of short pressure and technical weakness creates potential squeeze vulnerability if sentiment shifts, though the fundamental story hinges on execution risk in a regulated market.